BR112022017542A2 - Moléculas processadas por protease - Google Patents

Moléculas processadas por protease

Info

Publication number
BR112022017542A2
BR112022017542A2 BR112022017542A BR112022017542A BR112022017542A2 BR 112022017542 A2 BR112022017542 A2 BR 112022017542A2 BR 112022017542 A BR112022017542 A BR 112022017542A BR 112022017542 A BR112022017542 A BR 112022017542A BR 112022017542 A2 BR112022017542 A2 BR 112022017542A2
Authority
BR
Brazil
Prior art keywords
protease
molecules
processed
molecules processed
protein molecules
Prior art date
Application number
BR112022017542A
Other languages
English (en)
Portuguese (pt)
Inventor
Langer Thomas
Rao Ercole
WEIL Sandra
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of BR112022017542A2 publication Critical patent/BR112022017542A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Detergent Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112022017542A 2020-03-05 2021-03-05 Moléculas processadas por protease BR112022017542A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20305233 2020-03-05
PCT/EP2021/055673 WO2021176090A1 (en) 2020-03-05 2021-03-05 Protease-processed molecules

Publications (1)

Publication Number Publication Date
BR112022017542A2 true BR112022017542A2 (pt) 2022-10-18

Family

ID=71096648

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022017542A BR112022017542A2 (pt) 2020-03-05 2021-03-05 Moléculas processadas por protease

Country Status (15)

Country Link
US (1) US20230279151A1 (enExample)
EP (1) EP4114865B1 (enExample)
JP (1) JP7766608B2 (enExample)
KR (1) KR20220150345A (enExample)
CN (1) CN115210265A (enExample)
AU (1) AU2021231327A1 (enExample)
BR (1) BR112022017542A2 (enExample)
CA (1) CA3170452A1 (enExample)
DK (1) DK4114865T3 (enExample)
ES (1) ES3068539T3 (enExample)
IL (1) IL295958A (enExample)
MX (1) MX2022010958A (enExample)
PL (1) PL4114865T3 (enExample)
TW (1) TW202146463A (enExample)
WO (1) WO2021176090A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025199278A2 (en) * 2024-03-20 2025-09-25 Regeneron Pharmaceuticals, Inc. Masked multispecific antigen-binding molecules with cleavable linkers

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060252096A1 (en) * 2005-04-26 2006-11-09 Glycofi, Inc. Single chain antibody with cleavable linker
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
CN103068846B9 (zh) * 2010-08-24 2016-09-28 弗·哈夫曼-拉罗切有限公司 包含二硫键稳定性Fv片段的双特异性抗体
CN112225798B (zh) * 2011-05-17 2023-07-18 洛克菲勒大学 人类免疫缺陷病毒中和抗体及其使用方法
EP2729488A4 (en) * 2011-07-06 2015-01-14 Medimmune Llc PROCESS FOR PREPARING MULTIMANT POLYPEPTIDES
KR101963230B1 (ko) * 2011-12-26 2019-03-29 삼성전자주식회사 복수개의 단일 항체를 포함하는 단백질 복합체
EP3197916A2 (en) * 2014-09-25 2017-08-02 Amgen Inc. Protease-activatable bispecific proteins
EP3443006B1 (en) 2016-04-13 2023-08-02 Sanofi Trispecific and/or trivalent binding proteins

Also Published As

Publication number Publication date
KR20220150345A (ko) 2022-11-10
ES3068539T3 (en) 2026-06-01
JP2023516380A (ja) 2023-04-19
US20230279151A1 (en) 2023-09-07
PL4114865T3 (pl) 2026-05-25
CA3170452A1 (en) 2021-09-10
DK4114865T3 (da) 2026-04-27
CN115210265A (zh) 2022-10-18
JP7766608B2 (ja) 2025-11-10
IL295958A (en) 2022-10-01
MX2022010958A (es) 2022-10-07
TW202146463A (zh) 2021-12-16
EP4114865B1 (en) 2026-01-28
AU2021231327A1 (en) 2022-10-27
WO2021176090A1 (en) 2021-09-10
EP4114865A1 (en) 2023-01-11

Similar Documents

Publication Publication Date Title
MX2020008272A (es) Nucleasas diseñadas específicas de blancos.
CY1124834T1 (el) Αναστολεις της αλληλεπιδρασης της μηνινης-mll
PE20221893A1 (es) Anticuerpos contra glicoproteina de espicula anti-sars-cov-2 y fragmentos de union al antigeno
BR112019017403A2 (pt) composições e métodos para o tratamento de câncer
BR112022003956A2 (pt) Anticorpos anti-cd73
EA202192738A1 (ru) Трициклические соединения, обеспечивающие разрушение белка ikaros и белка aiolos
BR112017026467A2 (pt) uso de exossomos para o tratamento de doença
BR112018000542A2 (pt) composições de irna de transtirretina (ttr) e métodos de uso das mesmas para o tratamento ou prevenção de doenças associadas à ttr
EA202091296A1 (ru) Расщепляющие ненейронный snare ботулинические нейротоксины
BR112018010216A2 (pt) purinonas como inibidores da protease específica da ubiquitina 1
AR110114A1 (es) ANTICUERPOS CONTRA b-AMILOIDE PIROGLUTAMATO Y SUS USOS
MA42606B1 (fr) Sels d'un inhibiteur de lsd1
BR112019005587A2 (pt) proteínas de ligação recombinantes e sua utilização
BR112021025645A2 (pt) Degradação de proteína alvo de parp14 para uso em terapia
EA202091964A1 (ru) КОМБИНИРОВАННЫЙ ПРОДУКТ НА ОСНОВЕ ИНГИБИТОРА Bcl-2 И ИНГИБИТОРА MDM2 И ЕГО ПРИМЕНЕНИЕ В ПРЕДУПРЕЖДЕНИИ И/ИЛИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ
MX2020005193A (es) Fusiones de anticuerpo anti-pd-l1 e il-7.
MX2019000047A (es) Inhibidores peptídicos de la acumulación de alfa-sinucleína basados en estructuras.
MX2021000155A (es) Moleculas de proteina multifuncionales que comprenden decorina y su uso.
JOP20230239A1 (ar) أجسام مضادة للنكتين-4 واستخدامتها
CR20240378A (es) Moléculas de unión anti -tdp-43 humanizadas y usos de las mismas
BR112014023642A2 (pt) proteína interferon-lambda4 (ifnl4), moléculas de anticorpo relacionadas, e usos das mesmas
CY1124667T1 (el) Τροποποιημενο rna που κωδικοποιει πολυπεπτιδια vegf-a, φαρμακοτεχνικες μορφες, και χρησεις που σχετιζονται με αυτα
ECSP20083339A (es) Proteínas inmunodominantes y fragmentos en esclerosis múltiple
MX2021015961A (es) Moleculas novedosas.
MX2021011596A (es) Compuestos y composiciones como moduladores de se?alizacion tlr.